X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
Through the acquisition, Lilly expand its immunology pipeline by including, DICE therapeutics' oral IL-17 inhibitors, DC-806 and DC-853. DC-806 is an oral small molecule and a validated drug target for the treatment of autoimmune and inflammatory diseases, including psoriasis.
Lead Product(s): DC-806
Therapeutic Area: Dermatology Product Name: DC-806
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Eli Lilly
Deal Size: $2,400.0 million Upfront Cash: $2,400.0 million
Deal Type: Acquisition August 09, 2023
Details:
Through the acquisition, Lilly expand its immunology pipeline by including, DICE therapeutics' oral IL-17 inhibitors, DC-806 and DC-853. DC-806 is an oral small molecule and a validated drug target for the treatment of autoimmune and inflammatory diseases, including psoriasis.
Lead Product(s): DC-806
Therapeutic Area: Dermatology Product Name: DC-806
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Eli Lilly
Deal Size: $2,400.0 million Upfront Cash: $2,400.0 million
Deal Type: Acquisition June 20, 2023
Details:
Company expects to use the net proceeds from the offering, for general corporate purposes and working capital, including the development of its drug product candidates including DC-806.
Lead Product(s): DC-806
Therapeutic Area: Dermatology Product Name: DC-806
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: BofA Securities
Deal Size: $345.0 million Upfront Cash: Undisclosed
Deal Type: Public Offering October 17, 2022
Details:
Company expects to use the net proceeds from the offering, for general corporate purposes and working capital, including the development of its drug product candidates including DC-806.
Lead Product(s): DC-806
Therapeutic Area: Dermatology Product Name: DC-806
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: BofA Securities
Deal Size: $300.0 million Upfront Cash: Undisclosed
Deal Type: Public Offering October 12, 2022
Details:
DC-806 is well tolerated with an excellent safety profile across all dose groups in healthy volunteers and psoriasis patients with a robust PK profile and clear pharmacodynamic effects on two distinct biomarkers at both high and low doses of DC-806.
Lead Product(s): DC-806
Therapeutic Area: Dermatology Product Name: DC-806
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 11, 2022
Details:
DC-806 is an orally-available, small molecule antagonist of the pro-inflammatory cytokine, interleukin-17 (IL-17), which is a validated drug target for the treatment of a variety of autoimmune and inflammatory diseases, including psoriasis.
Lead Product(s): DC-806
Therapeutic Area: Dermatology Product Name: DC-806
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 21, 2022
Details:
S011806 is an orally available, small molecule antagonist of the pro-inflammatory signaling molecule IL-17, an immune cell-derived cytokine that is produced in response to infection by certain microorganisms.
Lead Product(s): S011806
Therapeutic Area: Dermatology Product Name: S011806
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 25, 2021
Details:
Proceeds of the financing are expected to be used to support advancement of the Company’s preclinical IL-17 antagonist, S011806 into clinical development, advancement of preclinical α4ß7 and αVß1/αVß6 integrin programs, pipeline expansion and other general corporate purposes.
Lead Product(s): S011806
Therapeutic Area: Dermatology Product Name: S011806
Highest Development Status: IND EnablingProduct Type: Small molecule
Partner/Sponsor/Collaborator: RA Capital Management
Deal Size: $60.0 million Upfront Cash: Undisclosed
Deal Type: Series C Financing August 24, 2021
Details:
Financing proceeds will support the progression of the Company’s first-in-class, oral IL-17 antagonist into clinical trials and advancement of its PPI antagonist pipeline.
Lead Product(s): Undisclosed
Therapeutic Area: Dermatology Product Name: Undisclosed
Highest Development Status: PreclinicalProduct Type: Small molecule
Partner/Sponsor/Collaborator: RA Capital Management
Deal Size: $80.0 million Upfront Cash: Undisclosed
Deal Type: Series C Financing January 08, 2021
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
